The individual in this role is the strategic architect of the company and is responsible for refining and developing the roadmap to execute long-term strategic vision for Aimmune Therapeutics, as a part of NHSc.
This role is critical as part of Aimmune’s journey to transform from a biotech enterprise to a thriving and differentiated pharmaceutical organization with deep development expertise and robust commercial capabilities across assets.
The individual will also partner closely with the NHSc Business Development Team to guide and direct future external partnership and Business Development opportunities and ensure the strategic direction of Aimmune is being realized.
This person will oversee Aimmune’s strategic alliances, and work to transition partnerships from the BD organization post close.
As we continue the integration efforts of Aimmune and NHSc, this role will also be responsible for ensuring continued momentum towards the achievement of critical integration milestones and oversee the successful integration of future acquisitions, helping the organization to realize.
Aligning with Aimmune’s corporate values of integrity and excellence, this role will have a significant impact on the evolution of Aimmune Therapeutics as a successful and differentiated pharmaceutical enterprise.
Key Responsibilities:
• Develop and manage Aimmune vision and long-term strategic roadmap in conjunction with NHSc and Nestle Corporate
• Set the company’s corporate objectives each year
• Manage / optimize cross-functional business processes
• Identify, develop business cases for and manage enterprise transformation initiatives (including integration of future assets and major capital expediters)
• Partner with the Finance function to deliver updates to the company’s long-range plan each year, and help co-ordinate the annual business planning process in partnership with NHSc
• Partner with Nestle Health Sciences (NHSc) Business Development resources to identify external assets to advance the corporate strategy.
• Provide a strategic sounding board to the CEO, and the Aimmune Leadership Team, to ensure that goals and objectives aligned to achieving the company vision are being achieved, and that priorities are being communicated effectively
• Support the process for preparing and distributing materials to the NHSc Leadership Team as part of the Quarterly Business Review process
Preferred Qualifications:
• BS/BA, advanced degree preferred in Science or Business, MBA or management consulting experience a plus
• 10+ years’ leadership experience driving growth in the life sciences, with at least 3-5 years directly leading a team
• Core experience in one of the following areas, with demonstrated understanding of other key business functions: commercial, business development, product development or organizational development
• Willingness to work hard, self-motivated and take direction while anticipating problems and devising solutions without explicit guidance
• The ability to work well under tight deadlines and to respond to rapidly changing demands
• Exceptional level of organizational, communication, presentation and management skills
• Emotionally intelligent individual who thrives in a fast-moving, dynamic environment within a complex and fast-changing industry
• Ability to influence executive leadership and key stakeholders
• Ability to build and maintain strong cross-functional relationships, lead and drive results without direct management authority
• Deep desire to have a meaningful impact on patient lives.
About Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies and food digestion & absorption.
Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
In the area of food digestion and absorption, we offer treatments for Exocrine Pancreatic Insufficiency (EPI), a disorder where the pancreas does not make enough enzymes due to cystic fibrosis or other conditions